drugset / Trial / NCT03219840

Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis

NCT03219840

RandomizedCrossoverQuadruple-blindPrevention

Summary

This placebo-controlled, double-blinded, randomized crossover study evaluates the plaque and gingivitis reducing capacity of Cetylpyridium Chloride (CPC) chewing gum, with mechanical oral hygiene. The study will enroll 73 students, faculty, and staff from the UTHealth School of Dentistry. Half of the eligible participants will be randomly assigned to get the CPC gum in the first treatment period (21 days), a wash-out period of 21 days, and then a placebo gum in the second treatment period (21 days). The other half will be assigned to follow the same schedule but with the treatment reversed. A statistician will perform the randomization. Primary outcomes are assessed by validated tools, such as the Plaque Index (PI), Gingival Index (GI), and percent of bleeding sites on probe (BOP).

Timeline

Start
2017-10-18
Primary completion
2018-09-08
Completion
2018-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetylpyridinium Small molecule 0.09 %

Indications